Artemisinic Acid Market (2023 - 2030)

Artemisinic Acid Market Summary

The COVID-19 pandemic negatively impacted the demand for malaria treatment initially as treatment preference was given to those that were affected by COVID-19. In March 2020. The WHO urged countries with a high rate of malaria cases in Africa to continue providing malaria services such as detection, treatment, and prevention. This is likely to have boosted the market during the pandemic period. Moreover, the initiatives by these public organizations to eradicate malaria by improving access to treatment are expected to support the market in the post-pandemic period.

Malaria is a life-threatening disease. According to the WHO, in 2021, over half of the total global population was at risk of malaria. The WHO also states that in the same year, over 247 million malaria cases were reported globally. WHO also added that over 619,000 deaths due to malaria were reported in the same year. The high burden of the disease and the significant number of deaths associated with malaria are expected to improve the demand for newer treatment options and create opportunities for artemisinic acid in disease treatment.

Public organizations across the globe have taken initiatives to improve access to effective treatment of malaria to reduce the deaths associated with the disease. For instance, in 2021, WHO, as part of the Malaria Elimination initiative, aimed to provide access to malaria diagnosis, prevention, and treatments as part of universal health coverage. Such initiatives by the public organization to provide treatment at a low cost are expected to improve the demand for treatments such as artemisinic acid and thus support market growth.

In endemic countries around the globe, artemisinin-based combination therapies (ACT) are currently used as the first line of malaria treatment. Artemisinin is made by synthesizing artemisinic acid. The high usage of Artemisinin and the cost-effectiveness of Artemisinin prepared from artemisinic acid is expected to create the demand for the production of artemisinic acid for treating malaria. This is also expected to improve its adoption, especially in endemic countries, and hence support market growth.

Type Insights

The antimalarial tablets segment led the market with the highest revenue share of 80.8% in 2022. The segment is also expected to grow at the fastest rate of 4.3% CAGR. Based on type, the market is segmented into antimalarial injections and antimalarial tablets. Tablets are an oral way of drug administration. Tablets are self-administering and do not require a trained physician for drug administration, which is one of the major reasons for the high acceptance of tablet formulations. Moreover, tablet formulations offer high patient compliance, accurate dosing, control of drug release, and stability. This further improves the demand for antimalarial tablet formulations in the market.

The antimalarial injection segment is anticipated to witness a growth rate of 4.18% over the forecast period. Antimalarial injections are used for severe malaria cases, especially during the time of emergencies. The high bioavailability of injectable formulations leading to the immediate onset of action is the prime factor for its demand in the market. The high number of hospitalizations due to malaria worldwide is expected to boost the segment market growth further.

Regional Insights

The Middle East region registered the largest market share of 56.89% in 2022. The regional market growth is expected to grow at the fastest rate of 4.31% across the forecast. Africa is one of the major countries which suffers significantly from malaria. For instance, UNICEF reports that every minute a child under 5 years dies from malaria in Africa. In MEA, public organizations are keen to provide treatment to reduce the number of deaths associated with the disease.

For instance, the WHO in 2021 stated that The African Region of the WHO accounts for a large part of the global malaria burden. In 2021, the region accounted to have 95% of malaria cases and 96% of malaria deaths. The high burden of the disease and the initiative by public organizations to raise awareness regarding the treatment for malaria is benefiting the growth of the regional market.

The Asia Pacific region accounted for the second largest share of 31.83% in 2022. Countries such as India, Pakistan, Indonesia, and others suffer from a high burden of malaria cases in the region. India is known for the world's third-highest malaria burden. The initiatives taken by public organizations in the APAC countries to reduce the burden of malaria and provide proper treatment are expected to boost the market in Asia Pacific. For instance, The government of India developed a National Strategic Plan (NSP, 2017-2022) and National Framework for Malaria Elimination (2016-2030) to eradicate malaria disease by providing treatment at a low cost. Such initiatives are likely to support the market in Asia Pacific in the forecast.

Key Companies & Market Share Insights

Market players are undertaking various strategic initiatives such as the launch of new product partnerships, collaborations, mergers, and acquisitions aiming to strengthen their product portfolio, and provide a competitive advantage. For instance, Rupus Global Limited, in May 2020, stated that they are about to launch about 50 products in the next 12 months in Africa and UAE for malaria, pain management, and cancer. These products also included artemisinin-based APIs. Such initiatives are likely to support market growth. Some prominent players in the global artemisinic acid market include:

• Sanofi

• KPC Pharmaceuticals, Inc

• Guilin Pharmaceutical Co., Ltd

• Calyx Chemicals and Pharmaceuticals Ltd.

• Novartis AG

• Ipca Laboratories Ltd.

• Cipla Inc.

• Shin Poong Pharm Co., Ltd.

• Rupus Global Limited

• AdvacarePharma

Artemisinic Acid Market